Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
09 04 2020
Historique:
received: 24 05 2019
accepted: 04 03 2020
pubmed: 11 3 2020
medline: 20 5 2021
entrez: 11 3 2020
Statut: epublish

Résumé

Chikungunya virus (CHIKV) infection causes acute febrile illness in humans, and some of these individuals develop a debilitating chronic arthritis that can persist for months to years for reasons that remain poorly understood. In this study from India, we characterized antibody response patterns in febrile chikungunya patients and further assessed the association of these initial febrile-phase antibody response patterns with protection versus progression to developing chronic arthritis. We found 5 distinct patterns of the antibody responses in the febrile phase: no CHIKV binding or neutralizing (NT) antibodies but PCR positive, IgM alone with no NT activity, IgM alone with NT activity, IgM and IgG without NT activity, and IgM and IgG with NT activity. A 20-month follow-up showed that appearance of NT activity regardless of antibody isotype or appearance of IgG regardless of NT activity during the initial febrile phase was associated with a robust protection against developing chronic arthritis in the future. These findings, while providing potentially novel insights on correlates of protective immunity against chikungunya-induced chronic arthritis, suggest that qualitative differences in the antibody response patterns that have evolved during the febrile phase can serve as biomarkers that allow prediction of protection or progression to chronic arthritis in the future.

Identifiants

pubmed: 32155134
pii: 130509
doi: 10.1172/jci.insight.130509
pmc: PMC7205261
doi:
pii:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI115651
Pays : United States

Références

Arthritis Rheumatol. 2018 Apr;70(4):484-495
pubmed: 29287308
Am J Trop Med Hyg. 2014 May;90(5):882-91
pubmed: 24639305
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Med Virol. 2016 Jun;88(6):923-30
pubmed: 26581026
Int J Infect Dis. 2019 Jul;84S:S57-S63
pubmed: 30658170
Clin Infect Dis. 2009 Sep 15;49(6):942-8
pubmed: 19663604
J Vector Borne Dis. 2006 Dec;43(4):151-60
pubmed: 17175699
J Virol. 2016 Apr 14;90(9):4402-4411
pubmed: 26889035
PLoS Negl Trop Dis. 2015 May 07;9(5):e0003764
pubmed: 25951202
J Clin Invest. 2017 Mar 1;127(3):737-749
pubmed: 28248203
PLoS One. 2019 Feb 1;14(2):e0211036
pubmed: 30707708
Indian J Med Res. 2015 Dec;142 Suppl:S111-5
pubmed: 26905236
Natl Med J India. 2006 Nov-Dec;19(6):315-22
pubmed: 17343016
PLoS Negl Trop Dis. 2011 Aug;5(8):e1279
pubmed: 21858242
Indian J Med Res. 2014 Mar;139(3):468-70
pubmed: 24820844
Ann Biol Clin (Paris). 1992;50(8):565-75
pubmed: 1294012
PLoS One. 2014 Oct 24;9(10):e111305
pubmed: 25343623
Front Cell Infect Microbiol. 2018 Oct 10;8:345
pubmed: 30364124
EMBO Mol Med. 2012 Apr;4(4):330-43
pubmed: 22389221
J Med Virol. 2014 Aug;86(8):1393-401
pubmed: 24523146
Viral Immunol. 2017 Dec;30(10):691-702
pubmed: 28910194
J Immunol. 2016 Dec 1;197(11):4210-4218
pubmed: 27864552
Infect Dis Clin North Am. 2019 Dec;33(4):1003-1025
pubmed: 31668189
Curr Opin Rheumatol. 2018 May;30(3):256-263
pubmed: 29389830
J Natl Med Assoc. 2006 Jul;98(7):1089-94
pubmed: 16895277
PLoS One. 2017 Feb 9;12(2):e0171989
pubmed: 28182795
Clin Infect Dis. 2017 Jul 1;65(1):133-140
pubmed: 28379375
J Virol. 2016 Nov 28;90(24):11259-11278
pubmed: 27707928
Viruses. 2018 May 30;10(6):
pubmed: 29849008
J Infect Public Health. 2018 Jul - Aug;11(4):586-591
pubmed: 28993172
J Virol. 2012 Dec;86(23):13005-15
pubmed: 23015702
Euro Surveill. 2006 Feb 02;11(2):E060202.3
pubmed: 16804203
Antiviral Res. 2013 Sep;99(3):345-70
pubmed: 23811281
Microbes Infect. 2019 Jan - Feb;21(1):4-9
pubmed: 29959095
PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005238
pubmed: 28125580
WHO South East Asia J Public Health. 2014 Jan-Mar;3(1):22-26
pubmed: 28607250

Auteurs

Kaustuv Nayak (K)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Vineet Jain (V)

Department of Medicine, Hamdard Institute of Medical Sciences and Research (HIMSAR), Jamia Hamdard, New Delhi, India.

Manpreet Kaur (M)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Naushad Khan (N)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Kamalvishnu Gottimukkala (K)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Charu Aggarwal (C)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Rohit Sagar (R)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Shipra Gupta (S)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Ramesh Chandra Rai (RC)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Kritika Dixit (K)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Mohammad Islamuddin (M)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Wajihul Hasan Khan (WH)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Anil Verma (A)

Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Deepti Maheshwari (D)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Yadya M Chawla (YM)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Elluri Seetharami Reddy (ES)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Harekrushna Panda (H)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Pragati Sharma (P)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Priya Bhatnagar (P)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Prabhat Singh (P)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Siva Raghavendhar B (S)

Kusuma School of Biological Sciences, Indian Institute of Technology (IIT), New Delhi, India.

Ashok Kumar Patel (AK)

Kusuma School of Biological Sciences, Indian Institute of Technology (IIT), New Delhi, India.

Vinod H Ratageri (VH)

Department of Pediatrics, Karnataka Institute of Medical Sciences (KIMS), Hubli, Karnataka, India.

Anmol Chandele (A)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.

Pratima Ray (P)

Department of Biotechnology, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, India.

Kaja Murali-Krishna (K)

ICGEB-Emory Vaccine Centre, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, India.
Emory Vaccine Center and.
Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH